ORION CORP.B UNSP.ADR 1/2 Cash Flow Conversion Efficiency
ORION CORP.B UNSP.ADR 1/2 cash flow conversion efficiency. Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) has a cash flow conversion efficiency ratio of 0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€37.00 Million ≈ $43.26 Million USD) by net assets (€1.12 Billion ≈ $1.31 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ORION CORP.B UNSP.ADR 1/2 (2022–2025)
Cash flow conversion efficiency of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025. This chart illustrates how ORION CORP.B UNSP.ADR 1/2's cash flow conversion efficiency has evolved over time, based on yearly financial data. View OFK0 stock price for real-time trading data and today's change.
ORION CORP.B UNSP.ADR 1/2 Cash Flow Conversion Ratio Explained
ORION CORP.B UNSP.ADR 1/2 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ORION CORP.B UNSP.ADR 1/2 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ORION CORP.B UNSP.ADR 1/2 ranked by their cash flow conversion efficiency. Also see ORION CORP.B UNSP.ADR 1/2 (OFK0) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
N/A |
|
Brixmor Property
NYSE:BRX
|
0.068x |
|
Western Alliance Bancorporation
NYSE:WAL
|
-0.044x |
|
Kinsale Capital Group Inc
NYSE:KNSL
|
0.119x |
|
Svenska Cellulosa Aktiebolaget SCA (publ)
ST:SCA-B
|
0.010x |
|
GETLINK ADR EO-40
F:TNU
|
N/A |
|
RATIONAL Aktiengesellschaft
XETRA:RAA
|
0.126x |
|
WT Microelectronics Co Ltd
TW:3036
|
0.234x |
Annual Cash Flow Conversion Efficiency for ORION CORP.B UNSP.ADR 1/2 (2022–2025)
The table below shows the annual cash flow conversion efficiency of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025. Review free cash flow generation of ORION CORP.B UNSP.ADR 1/2 to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.28 Billion ≈ $1.50 Billion |
€316.80 Million ≈ $370.37 Million |
0.247x | -15.52% |
| 2024-12-31 | €1.00 Billion ≈ $1.17 Billion |
€293.40 Million ≈ $343.02 Million |
0.292x | +118.37% |
| 2023-12-31 | €890.10 Million ≈ $1.04 Billion |
€119.00 Million ≈ $139.12 Million |
0.134x | -72.05% |
| 2022-12-31 | €908.10 Million ≈ $1.06 Billion |
€434.40 Million ≈ $507.86 Million |
0.478x | -- |
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more